Adam Palermo

This inventor holds 13 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent. Top assignees: Decibel Therapeutics, Inc., Genzyme Corporation, Regeneron Pharmaceuticals, Inc.. Active years: 2019-2026.

USPTO Granted Patents = 13 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 8)

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 11(Granted Patents)

Location History:

Boston, MA (US) (2019 - 2023)
Cambridge, MA (US) (2023)

Company Filing History:

7 out of 14

Decibel Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741034 - COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (2026-09-22),

2. 12589168 - COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (2026-03-31),

3. 12545930 - COCHLEAR INNER HAIR CELL PROMOTERS AND USES THEREOF (2026-02-10),

4. 12534739 - AAV1 VECTORS AND USES THEREOF FOR TREATMENT OF OTIC INDICATIONS (2026-01-27),

5. 12410442 - Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems (2025-09-09),

6. 12331296 - Variant RNAi (2025-06-17),

7. 12252520 - Myosin 15 promoters and uses thereof (2025-03-18),

8. 12233136 - Myosin 15 promoters and uses thereof (2025-02-25),

9. 11781137 - Variant RNAi (2023-10-10),

10. 11660353 - Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems (2023-05-30),

11. 11603529 - Variant RNAi (2023-03-14),

12. 10760079 - Variant RNAi (2020-09-01),

13. 10450563 - Variant RNAi (2019-10-22),

Title: The Innovative Contributions of Adam Palermo

Introduction

Adam Palermo is a notable inventor based in Boston, MA (US). He has made significant strides in the field of biotechnology, particularly in the development of RNA interference (RNAi) technologies aimed at treating Huntington's disease. With a total of 13 patents to his name, Palermo's work is paving the way for new therapeutic approaches.

Latest Patents

Palermo's latest patents focus on innovative RNAi molecules designed to combat Huntington's disease. One of his key inventions involves RNAi molecules that include a first strand containing a guide sequence and a second strand with a non-guide sequence. This non-guide sequence features a bulge opposite the seed region of the guide sequences, enhancing the efficacy of the treatment. Additionally, his patents encompass expression cassettes, vectors such as rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors, as well as cells, viral particles, and pharmaceutical compositions containing the RNAi. These inventions are crucial for developing methods and kits related to the use of RNAi in treating Huntington's disease.

Career Highlights

Adam Palermo is currently associated with Genzyme Corporation, a leading biotechnology company. His work at Genzyme has allowed him to focus on groundbreaking research and development in the field of genetic therapies. His contributions have not only advanced scientific understanding but also provided hope for patients suffering from debilitating conditions.

Collaborations

Palermo collaborates with talented professionals in his field, including Brenda Richards and Lisa M Stanek. These collaborations enhance the innovative potential of his research and contribute to the success of his projects.

Conclusion

Adam Palermo's contributions to the field of biotechnology, particularly in RNAi technologies for treating Huntington's disease, highlight his role as a leading inventor. His work continues to inspire advancements in medical science and offers hope for future therapies.